메뉴 건너뛰기




Volumn 65, Issue 6, 2016, Pages 701-713

Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer

Author keywords

Immunogenicity; Prostate cancer; STEAP1; TRAMP model; Vaccine

Indexed keywords

CANCER VACCINE; MODIFIED VACCINIA ANKARA VECTOR; MONOCLONAL ANTIBODY; PROGRAMMED CELL DEATH 1 MONOCLONAL ANTIBODY; PROSTATE ANTIGEN; PROSTATE SPECIFIC ANTIGEN; SIMIAN ADENOVIRUS VECTOR; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; STEAP PROTEIN, MOUSE;

EID: 84962780867     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1831-8     Document Type: Article
Times cited : (42)

References (50)
  • 2
    • 84872488155 scopus 로고    scopus 로고
    • Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
    • COI: 1:CAS:528:DC%2BC3sXosl2lug%3D%3D, PID: 22865266
    • Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY et al (2013) Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 62(1):137–147. doi:10.1007/s00262-012-1317-2
    • (2013) Cancer Immunol Immunother , vol.62 , Issue.1 , pp. 137-147
    • Sheikh, N.A.1    Petrylak, D.2    Kantoff, P.W.3    Dela Rosa, C.4    Stewart, F.P.5    Kuan, L.Y.6
  • 3
    • 84996548609 scopus 로고    scopus 로고
    • Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer
    • Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B et al (2013) Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res 2(2):1331–1341. doi:10.1158/2326-6066.CIR-13-0108
    • (2013) Cancer Immunol Res , vol.2 , Issue.2 , pp. 1331-1341
    • Gulley, J.L.1    Madan, R.A.2    Tsang, K.Y.3    Jochems, C.4    Marté, J.L.5    Farsaci, B.6
  • 5
    • 84885374134 scopus 로고    scopus 로고
    • Six-transmembrane epithelial antigen of the prostate-1 plays a role for in vivo tumor growth via intercellular communication
    • COI: 1:CAS:528:DC%2BC3sXhtlCgtLnO, PID: 23916873
    • Yamamoto T, Tamura Y, Kobayashi J, Kamiguchi K, Hirohashi Y, Miyazaki A et al (2013) Six-transmembrane epithelial antigen of the prostate-1 plays a role for in vivo tumor growth via intercellular communication. Exp Cell Res 319:2617–2626. doi:10.1016/j.yexcr.2013.07.025
    • (2013) Exp Cell Res , vol.319 , pp. 2617-2626
    • Yamamoto, T.1    Tamura, Y.2    Kobayashi, J.3    Kamiguchi, K.4    Hirohashi, Y.5    Miyazaki, A.6
  • 7
    • 84890801992 scopus 로고    scopus 로고
    • STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score
    • PID: 24239460
    • Gomes IM, Arinto P, Lopes C, Santos CR, Maia CJ (2014) STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. Urol Oncol 32(1):53.e23-9. doi:10.1016/j.urolonc.2013.08.028
    • (2014) Urol Oncol , vol.32 , Issue.1
    • Gomes, I.M.1    Arinto, P.2    Lopes, C.3    Santos, C.R.4    Maia, C.J.5
  • 8
    • 33847075902 scopus 로고    scopus 로고
    • In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer
    • PID: 17283172
    • Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM (2007) In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 67:1344–1351. doi:10.1158/0008-5472.CAN-06-2996
    • (2007) Cancer Res , vol.67 , pp. 1344-1351
    • Garcia-Hernandez Mde, L.1    Gray, A.2    Hubby, B.3    Kast, W.M.4
  • 9
    • 84863734927 scopus 로고    scopus 로고
    • A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity
    • COI: 1:CAS:528:DC%2BC38XhtVyisrvN, PID: 22808149
    • Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC et al (2012) A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 7:e40385. doi:10.1371/journal.pone.0040385
    • (2012) PLoS ONE , vol.7 , pp. e40385
    • Dicks, M.D.1    Spencer, A.J.2    Edwards, N.J.3    Wadell, G.4    Bojang, K.5    Gilbert, S.C.6
  • 10
    • 73449147009 scopus 로고    scopus 로고
    • Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
    • COI: 1:CAS:528:DC%2BC3cXhtFaiurY%3D, PID: 19858306
    • Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A et al (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78:145–153. doi:10.1128/IAI.00740-09
    • (2010) Infect Immun , vol.78 , pp. 145-153
    • Reyes-Sandoval, A.1    Berthoud, T.2    Alder, N.3    Siani, L.4    Gilbert, S.C.5    Nicosia, A.6
  • 11
    • 84875150077 scopus 로고    scopus 로고
    • Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1
    • PID: 23485942
    • Lambe T, Carey JB, Li Y, Spencer AJ, van Laarhoven A, Mullarkey CE et al (2013) Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci Rep 3:1443. doi:10.1038/srep01443
    • (2013) Sci Rep , vol.3 , pp. 1443
    • Lambe, T.1    Carey, J.B.2    Li, Y.3    Spencer, A.J.4    van Laarhoven, A.5    Mullarkey, C.E.6
  • 12
    • 84914692091 scopus 로고    scopus 로고
    • Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice
    • PID: 25230940
    • Ondondo B, Abdul-Jawad S, Bridgeman A, Hanke T (2014) Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice. Clin Vaccine Immunol 21:1565–1572. doi:10.1128/cvi.00587-14
    • (2014) Clin Vaccine Immunol , vol.21 , pp. 1565-1572
    • Ondondo, B.1    Abdul-Jawad, S.2    Bridgeman, A.3    Hanke, T.4
  • 13
    • 84889253599 scopus 로고    scopus 로고
    • Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus–MVA immunisation
    • PID: 24284865
    • Ewer KJ, O’Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A et al (2013) Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus–MVA immunisation. Nat Commun 4:2836. doi:10.1038/ncomms3836
    • (2013) Nat Commun , vol.4 , pp. 2836
    • Ewer, K.J.1    O’Hara, G.A.2    Duncan, C.J.3    Collins, K.A.4    Sheehy, S.H.5    Reyes-Sandoval, A.6
  • 14
    • 84895508255 scopus 로고    scopus 로고
    • Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens
    • COI: 1:CAS:528:DC%2BC2cXps1GhsA%3D%3D, PID: 24374965
    • Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T et al (2014) Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther 22:668–674. doi:10.1038/mt.2013.284
    • (2014) Mol Ther , vol.22 , pp. 668-674
    • Antrobus, R.D.1    Coughlan, L.2    Berthoud, T.K.3    Dicks, M.D.4    Hill, A.V.5    Lambe, T.6
  • 15
    • 84895904764 scopus 로고    scopus 로고
    • Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
    • COI: 1:CAS:528:DC%2BC2cXjtVOgsQ%3D%3D, PID: 24166483
    • Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U et al (2014) Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 22:464–475. doi:10.1038/mt.2013.248
    • (2014) Mol Ther , vol.22 , pp. 464-475
    • Borthwick, N.1    Ahmed, T.2    Ondondo, B.3    Hayes, P.4    Rose, A.5    Ebrahimsa, U.6
  • 16
    • 84908876253 scopus 로고    scopus 로고
    • A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
    • PID: 25378645
    • Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW et al (2014) A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 6:261ra153. doi:10.1126/scitranslmed.3009185
    • (2014) Sci Transl Med , vol.6 , pp. 261ra153
    • Swadling, L.1    Capone, S.2    Antrobus, R.D.3    Brown, A.4    Richardson, R.5    Newell, E.W.6
  • 17
    • 84927729727 scopus 로고    scopus 로고
    • Evaluation of the efficacy of ChAd63–MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals
    • PID: 25336730
    • Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA et al (2015) Evaluation of the efficacy of ChAd63–MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis 211:1076–1086. doi:10.1093/infdis/jiu579
    • (2015) J Infect Dis , vol.211 , pp. 1076-1086
    • Hodgson, S.H.1    Ewer, K.J.2    Bliss, C.M.3    Edwards, N.J.4    Rampling, T.5    Anagnostou, N.A.6
  • 18
    • 84863605162 scopus 로고    scopus 로고
    • Area under the curve as a tool to measure kinetics of tumor growth in experimental animals
    • COI: 1:CAS:528:DC%2BC38XptlWqsro%3D, PID: 22698786
    • Duan F, Simeone S, Wu R, Grady J, Mandoiu I, Srivastava PK (2012) Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. J Immunol Methods 382:224–228. doi:10.1016/j.jim.2012.06.005
    • (2012) J Immunol Methods , vol.382 , pp. 224-228
    • Duan, F.1    Simeone, S.2    Wu, R.3    Grady, J.4    Mandoiu, I.5    Srivastava, P.K.6
  • 19
    • 0029791591 scopus 로고    scopus 로고
    • A transgenic mouse prostate cancer model
    • COI: 1:STN:280:DyaK2s%2FhslGktA%3D%3D, PID: 8864193
    • Gingrich JR, Greenberg NM (1996) A transgenic mouse prostate cancer model. Toxicol Pathol 24:502–504. doi:10.1177/019262339602400414
    • (1996) Toxicol Pathol , vol.24 , pp. 502-504
    • Gingrich, J.R.1    Greenberg, N.M.2
  • 20
    • 77950593165 scopus 로고    scopus 로고
    • IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer
    • COI: 1:CAS:528:DC%2BC3cXkvFCgsbc%3D, PID: 20304037
    • Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M et al (2010) IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 28(20):3548–3557. doi:10.1016/j.vaccine.2010.03.007
    • (2010) Vaccine , vol.28 , Issue.20 , pp. 3548-3557
    • Martini, M.1    Testi, M.G.2    Pasetto, M.3    Picchio, M.C.4    Innamorati, G.5    Mazzocco, M.6
  • 21
    • 84953865143 scopus 로고    scopus 로고
    • Randomized phase II trial of cocetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: a trial of the ECOG-ACRIN cancer research group (E1809)
    • PID: 26111351
    • McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA et al (2015) Randomized phase II trial of cocetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: a trial of the ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother 11:2469–2474. doi:10.1080/21645515.2015.1062190
    • (2015) Hum Vaccin Immunother , vol.11 , pp. 2469-2474
    • McNeel, D.G.1    Chen, Y.H.2    Gulley, J.L.3    Dwyer, A.J.4    Madan, R.A.5    Carducci, M.A.6
  • 22
    • 84997666967 scopus 로고    scopus 로고
    • Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
    • PID: 26082837
    • Kubler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F et al (2015) Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer 3:26. doi:10.1186/s40425-015-0068-y
    • (2015) J Immunother Cancer , vol.3 , pp. 26
    • Kubler, H.1    Scheel, B.2    Gnad-Vogt, U.3    Miller, K.4    Schultze-Seemann, W.5    Vom Dorp, F.6
  • 23
    • 79952834825 scopus 로고    scopus 로고
    • Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination
    • COI: 1:CAS:528:DC%2BC3MXjsVWlsrk%3D, PID: 21416326
    • Wang Z, Yang S, Zhou L, Du H, Mo W, Zeng Y (2011) Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination. Sci China Life Sci 54:263–266. doi:10.1007/s11427-011-4147-0
    • (2011) Sci China Life Sci , vol.54 , pp. 263-266
    • Wang, Z.1    Yang, S.2    Zhou, L.3    Du, H.4    Mo, W.5    Zeng, Y.6
  • 24
    • 84866858197 scopus 로고    scopus 로고
    • Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens
    • COI: 1:CAS:528:DC%2BC38XhsVOmu7nP, PID: 23049876
    • Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D et al (2012) Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS ONE 7:e45840. doi:10.1371/journal.pone.0045840
    • (2012) PLoS ONE , vol.7 , pp. e45840
    • Ratto-Kim, S.1    Currier, J.R.2    Cox, J.H.3    Excler, J.L.4    Valencia-Micolta, A.5    Thelian, D.6
  • 25
    • 84919487863 scopus 로고    scopus 로고
    • A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
    • PID: 25522180
    • de Barra E, Hodgson SH, Ewer KJ, Bliss CM, Hennigan K, Collins A et al (2014) A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS ONE 9:e115161. doi:10.1371/journal.pone.0115161
    • (2014) PLoS ONE , vol.9 , pp. e115161
    • de Barra, E.1    Hodgson, S.H.2    Ewer, K.J.3    Bliss, C.M.4    Hennigan, K.5    Collins, A.6
  • 26
    • 79151473356 scopus 로고    scopus 로고
    • Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression
    • COI: 1:CAS:528:DC%2BC3MXht1yqsLc%3D, PID: 21182993
    • Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, Esteban M (2011) Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 29:1504–1513. doi:10.1016/j.vaccine.2010.12.016
    • (2011) Vaccine , vol.29 , pp. 1504-1513
    • Krupa, M.1    Canamero, M.2    Gomez, C.E.3    Najera, J.L.4    Gil, J.5    Esteban, M.6
  • 27
    • 67049155480 scopus 로고    scopus 로고
    • Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer
    • Kim S, Lee JB, Lee GK, Chang J (2011) Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate 69(9):938–948. doi:10.1002/pros.20942
    • (2011) Prostate , vol.69 , Issue.9 , pp. 938-948
    • Kim, S.1    Lee, J.B.2    Lee, G.K.3    Chang, J.4
  • 28
    • 79960732805 scopus 로고    scopus 로고
    • Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity
    • COI: 1:CAS:528:DC%2BC3MXpt1yht7c%3D, PID: 21538347
    • Sierro S, Donda A, Perret R, Guillaume P, Yagita H, Levy F et al (2011) Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 41:2217–2228. doi:10.1002/eji.201041235
    • (2011) Eur J Immunol , vol.41 , pp. 2217-2228
    • Sierro, S.1    Donda, A.2    Perret, R.3    Guillaume, P.4    Yagita, H.5    Levy, F.6
  • 29
    • 33747179250 scopus 로고    scopus 로고
    • The Steap proteins are metalloreductases
    • COI: 1:CAS:528:DC%2BD28Xot1ymu7g%3D, PID: 16609065
    • Ohgami RS, Campagna DR, McDonald A, Fleming MD (2006) The Steap proteins are metalloreductases. Blood 108:1388–1394. doi:10.1182/blood-2006-02-003681
    • (2006) Blood , vol.108 , pp. 1388-1394
    • Ohgami, R.S.1    Campagna, D.R.2    McDonald, A.3    Fleming, M.D.4
  • 30
    • 0035421307 scopus 로고    scopus 로고
    • Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice
    • COI: 1:CAS:528:DC%2BD3MXlvVCgurg%3D, PID: 11479226
    • Yang DHG, Velders MP, Kwon ED, Kast WM (2001) Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 61:5857–5860
    • (2001) Cancer Res , vol.61 , pp. 5857-5860
    • Yang, D.H.G.1    Velders, M.P.2    Kwon, E.D.3    Kast, W.M.4
  • 31
    • 33748302110 scopus 로고    scopus 로고
    • STEAP, a prostate tumor antigen, is a target of human CD8+ T cells
    • COI: 1:CAS:528:DC%2BD28XptVWqtrY%3D, PID: 16622681
    • Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA et al (2006) STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother 55:1515–1523. doi:10.1007/s00262-006-0165-3
    • (2006) Cancer Immunol Immunother , vol.55 , pp. 1515-1523
    • Alves, P.M.1    Faure, O.2    Graff-Dubois, S.3    Cornet, S.4    Bolonakis, I.5    Gross, D.A.6
  • 32
    • 72049130810 scopus 로고    scopus 로고
    • Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages
    • COI: 1:CAS:528:DC%2BD1MXhsFGrsLvE, PID: 20006141
    • Gray A, Garcia-Hernandez M, West M, Kanodia S, Hubby B, Martin Kast W (2009) Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 27:G52–G59. doi:10.1016/j.vaccine.2009.09.106
    • (2009) Vaccine , vol.27 , pp. G52-G59
    • Gray, A.1    Garcia-Hernandez, M.2    West, M.3    Kanodia, S.4    Hubby, B.5    Martin, K.W.6
  • 33
    • 84891831962 scopus 로고    scopus 로고
    • Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor
    • PID: 24196579
    • McGray AJR, Robin H, Dannie B, Stephanie S, Ziqian Z, Florentina T et al (2013) Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther 22:206–218. doi:10.1038/mt.2013.255
    • (2013) Mol Ther , vol.22 , pp. 206-218
    • McGray, A.J.R.1    Robin, H.2    Dannie, B.3    Stephanie, S.4    Ziqian, Z.5    Florentina, T.6
  • 34
    • 84938777895 scopus 로고    scopus 로고
    • Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy
    • PID: 25964860
    • Kim YJ (2014) Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy. Oncoimmunology 3:e954868. doi:10.4161/21624011.2014.954868
    • (2014) Oncoimmunology , vol.3 , pp. e954868
    • Kim, Y.J.1
  • 35
    • 84891094512 scopus 로고    scopus 로고
    • Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes
    • PID: 24062984
    • Bellone M, Calcinotto A (2013) Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol 3:231. doi:10.3389/fonc.2013.00231
    • (2013) Front Oncol , vol.3 , pp. 231
    • Bellone, M.1    Calcinotto, A.2
  • 36
    • 84901022638 scopus 로고    scopus 로고
    • Oncolytic virus-mediated reversal of impaired tumor antigen presentation
    • PID: 24782988
    • Gujar SA, Lee PW (2014) Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front Oncol 4:77. doi:10.3389/fonc.2014.00077
    • (2014) Front Oncol , vol.4 , pp. 77
    • Gujar, S.A.1    Lee, P.W.2
  • 37
    • 0030743846 scopus 로고    scopus 로고
    • Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
    • COI: 1:CAS:528:DyaK2sXksl2ltrk%3D, PID: 9223321
    • Kwon E, Hurwitz AA, Foster B, Madias C, Feldhaus A, Greenberg NM et al (1997) Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 94:8099–8103. doi:10.1073/pnas.94.15.8099
    • (1997) Proc Natl Acad Sci USA , vol.94 , pp. 8099-8103
    • Kwon, E.1    Hurwitz, A.A.2    Foster, B.3    Madias, C.4    Feldhaus, A.5    Greenberg, N.M.6
  • 38
    • 33846506812 scopus 로고    scopus 로고
    • Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer
    • COI: 1:CAS:528:DC%2BD2sXntVGisg%3D%3D, PID: 17237372
    • Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA (2007) Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 178:1268–1276
    • (2007) J Immunol , vol.178 , pp. 1268-1276
    • Anderson, M.J.1    Shafer-Weaver, K.2    Greenberg, N.M.3    Hurwitz, A.A.4
  • 39
    • 84875689651 scopus 로고    scopus 로고
    • Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
    • COI: 1:CAS:528:DC%2BC3sXpvFWmurY%3D, PID: 23557194
    • Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ et al (2013) Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med 11:89. doi:10.1186/1479-5876-11-89
    • (2013) J Transl Med , vol.11 , pp. 89
    • Wada, S.1    Jackson, C.M.2    Yoshimura, K.3    Yen, H.R.4    Getnet, D.5    Harris, T.J.6
  • 40
    • 77951116334 scopus 로고    scopus 로고
    • Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses
    • COI: 1:CAS:528:DC%2BC3cXksFCgtrY%3D, PID: 20384522
    • Durrant LG, Pudney V, Spendlove I, Metheringham RL (2010) Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses. Expert Opin Biol Ther 10:735–748. doi:10.1517/14712591003769790
    • (2010) Expert Opin Biol Ther , vol.10 , pp. 735-748
    • Durrant, L.G.1    Pudney, V.2    Spendlove, I.3    Metheringham, R.L.4
  • 41
    • 80051646256 scopus 로고    scopus 로고
    • CD8+ T effector memory cells protect against liver-stage malaria
    • COI: 1:CAS:528:DC%2BC3MXptValsr0%3D, PID: 21715686
    • Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes E, Rollier CS et al (2011) CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 187:1347–1357. doi:10.4049/jimmunol.1100302
    • (2011) J Immunol , vol.187 , pp. 1347-1357
    • Reyes-Sandoval, A.1    Wyllie, D.H.2    Bauza, K.3    Milicic, A.4    Forbes, E.5    Rollier, C.S.6
  • 42
    • 84857505184 scopus 로고    scopus 로고
    • Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model
    • COI: 1:CAS:528:DC%2BC38Xis1Omu7s%3D, PID: 21761425
    • Bruno TC, Rothwell C, Grosso JF, Getnet D, Yen HR, Durham NM et al (2012) Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. Prostate 72:514–522. doi:10.1002/pros.21453
    • (2012) Prostate , vol.72 , pp. 514-522
    • Bruno, T.C.1    Rothwell, C.2    Grosso, J.F.3    Getnet, D.4    Yen, H.R.5    Durham, N.M.6
  • 43
    • 67349274372 scopus 로고    scopus 로고
    • Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth
    • COI: 1:CAS:528:DC%2BD1MXjsl2ns78%3D, PID: 19337234
    • Ahmad S, Casey G, Sweeney P, Tangney M, O’Sullivan GC (2009) Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther 17:1101–1108. doi:10.1038/mt.2009.66
    • (2009) Mol Ther , vol.17 , pp. 1101-1108
    • Ahmad, S.1    Casey, G.2    Sweeney, P.3    Tangney, M.4    O’Sullivan, G.C.5
  • 44
    • 84928062583 scopus 로고    scopus 로고
    • Immune checkpoint blockade: a common denominator approach to cancer therapy
    • PID: 25858804
    • Topalian S, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. doi:10.1016/j.ccell.2015.03.001
    • (2015) Cancer Cell
    • Topalian, S.1    Drake, C.G.2    Pardoll, D.M.3
  • 45
    • 84991038640 scopus 로고    scopus 로고
    • Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
    • PID: 24829751
    • Mkrtichyan M, Chong N, Eid R, Wallecha A, Singh R, Rothman J et al (2013) Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer 1:15. doi:10.1186/2051-1426-1-15
    • (2013) J Immunother Cancer , vol.1 , pp. 15
    • Mkrtichyan, M.1    Chong, N.2    Eid, R.3    Wallecha, A.4    Singh, R.5    Rothman, J.6
  • 46
    • 84905457466 scopus 로고    scopus 로고
    • Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors
    • COI: 1:CAS:528:DC%2BC2cXht1Gntr3E, PID: 24812273
    • Fu J, Malm I, Kadayakkara H, Levitsky H, Pardoll DM, Kim YJ (2014) Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 74:4042–4052. doi:10.1158/0008-5472.CAN-13-2685
    • (2014) Cancer Res , vol.74 , pp. 4042-4052
    • Fu, J.1    Malm, I.2    Kadayakkara, H.3    Levitsky, H.4    Pardoll, D.M.5    Kim, Y.J.6
  • 47
    • 84950283228 scopus 로고    scopus 로고
    • PD-1 or PD-L1 blockade restores anti-tumor efficacy following SSX2 epitope-modified DNA vaccine immunization
    • COI: 1:CAS:528:DC%2BC2MXht1yqtr7K, PID: 26041735
    • Rekoske B, Smith H, Olson B, Maricque B, McNeel D (2015) PD-1 or PD-L1 blockade restores anti-tumor efficacy following SSX2 epitope-modified DNA vaccine immunization. Cancer Immunol Res 3:946–955. doi:10.1158/2326-6066.CIR-14-0206
    • (2015) Cancer Immunol Res , vol.3 , pp. 946-955
    • Rekoske, B.1    Smith, H.2    Olson, B.3    Maricque, B.4    McNeel, D.5
  • 48
    • 77749279776 scopus 로고    scopus 로고
    • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    • COI: 1:CAS:528:DC%2BC3cXjtlKms7c%3D, PID: 20160101
    • Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275–4280. doi:10.1073/pnas.0915174107
    • (2010) Proc Natl Acad Sci USA , vol.107 , pp. 4275-4280
    • Curran, M.A.1    Montalvo, W.2    Yagita, H.3    Allison, J.P.4
  • 49
    • 84890284474 scopus 로고    scopus 로고
    • Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer
    • COI: 1:CAS:528:DC%2BC3sXhvVKhurfJ, PID: 23975756
    • Duraiswamy J, Freeman GJ, Coukos G (2013) Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 73:6900–6912. doi:10.1158/0008-5472.can-13-1550
    • (2013) Cancer Res , vol.73 , pp. 6900-6912
    • Duraiswamy, J.1    Freeman, G.J.2    Coukos, G.3
  • 50
    • 34548046956 scopus 로고    scopus 로고
    • B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy
    • COI: 1:CAS:528:DC%2BD2sXptVGlt7g%3D, PID: 17686830
    • Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA et al (2007) B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 67(16):7893–7900. doi:10.1158/0008-5472.can-07-1068
    • (2007) Cancer Res , vol.67 , Issue.16 , pp. 7893-7900
    • Roth, T.J.1    Sheinin, Y.2    Lohse, C.M.3    Kuntz, S.M.4    Frigola, X.5    Inman, B.A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.